Skip to main content
Download PDF

Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model

Journal of Neuroinflammation volume 17, Article number: 181 (2020) Cite this article

Abstract

Background

A subanesthetic dose of ketamine provides rapid and effective antidepressant effects, but the molecular mechanism remains elusive. It has been reported that overactivation of extrasynaptic GluN2B receptors is associated with the antidepressant effects of ketamine and the interaction between GluN2B and calcium/calmodulin-dependent protein kinase IIα (CaMKIIα) is important for GluN2B localization and activity. Here, we tested whether changes of CaMKIIα and GluN2B are involved in the antidepressant effects of ketamine.

Methods

Lipopolysaccharide (LPS) was injected intraperitoneally (i.p.) into male C57BL/6 mice. For the interventional study, mice were administrated with ketamine (10 mg/kg, i.p.) or a CaMKIIα inhibitor KN93. Behavioral alterations were evaluated by open-field, novelty-suppressed feeding, and forced-swimming tests. Physiological functions were evaluated by the body weight and fur coat state of mice. The levels of p-CaMKIIα, CaMKIIα, p-GluN2B, GluN2B, p-CREB, CREB, BDNF, GluR1, and GluR2 in the hippocampus were detected by western blotting. The interaction between GluN2B and CaMKIIα was studied using immunoprecipitation assay and small interfering RNA (siRNA) assays. The colocalizations of GluN2B/PSD95 and p-GluN2B/PSD95 were detected by immunofluorescence. The long-term potentiation (LTP) in SC-CA1 of the hippocampus was detected by electrophysiology.

Results

LPS injection induced depression-like behaviors, which were accompanied by significant increases in extrasynaptic p-CaMKIIα expression, extrasynaptic GluN2B localization, and phosphorylation and decreases in p-CREB, BDNF, and GluR1 expressions and LTP impairment. These changes were prevented by ketamine administration. Immunoprecipitation assay revealed that LPS induced an increase in the p-CaMKIIα–GluN2B interaction, which was attenuated by ketamine administration. SiRNA assay revealed that CaMKIIα knockdown reduced the level and number of clusters of GluN2B in the cultured hippocampal neurons. KN93 administration also reduced extrasynaptic p-CaMKIIα expression, extrasynaptic GluN2B localization, and phosphorylation and exerted antidepressant effects.

Conclusion

These results indicate that extrasynaptic CaMKIIα plays a key role in the cellular mechanism of ketamine’s antidepressant effect and it is related to the downregulation of extrasynaptic GluN2B localization and phosphorylation.

Background

Depression is a common clinical psychiatric disease, which affects about 16% of the global population and places a serious social burden [1]. However, traditional antidepressants often require several weeks or months of continuous medication to achieve their full therapeutic effect [2]. Therefore, it is urgent to find novel antidepressant drugs that act rapidly and effectively. A single subanesthetic dose of ketamine is known to produce rapid and sustained effect [3]. However, the molecular mechanism underlying ketamine’s antidepressant effects remains to be elucidated.

Calcium/calmodulin-dependent protein kinase II (CaMKII) is a Ser/Thr protein kinase that is highly abundant in the brain. The CaMKII family of proteins comprises 28 similar isoforms that are derived from four genes (α, β, γ, and δ) [4]. CaMKIIα is the predominant isoform in the hippocampus and is central to the transmission of synaptic signals and the regulation of synaptic morphology [5]. Preclinical studies have shown that stress-induced activation of hypocretin/orexin receptors produces depression-like behaviors via an increase in p-CaMKIIα in mice and that siRNA-mediated inhibition of CaMKIIα counteracted the stress-induced depression-like behaviors [6]. Furthermore, fluoxetine, a typical antidepressant, reduces the binding of transcription factor ΔfosB to CaMKIIα promoter and reduces CaMKII expression, and CaMKII overexpression blocks the antidepressant effects of fluoxetine in a chronic social defeat stress model [7]. In a recent study, it has been demonstrated that ketamine administration induces CaMKII autoinhibition (pT305 phosphorylation) first and then autoactivation (pT286), whereas CaMKII inhibitor tatCN21 pre-treatment prevented ketamine’s antidepressant effects [8]. Together, these studies suggest that CaMKIIα plays a critical role in the stress-induced depression-like behaviors and the antidepressant effects of ketamine. However, whether CaMKIIα is involved in ketamine’s antidepressant effect in the lipopolysaccharide (LPS)-induced depression model is unclear.

N-methyl-d-aspartate receptors (NMDARs) are ionotropic glutamate receptors consisting of an essential GluN1 subunit and one or more regulatory GluN2 subunits (GluN2A–D). Because of the different localization of NMDARs on the synapse, they can be further divided into synaptic NMDARs and extrasynaptic NMDARs. Immunofluorescence and immunogold studies identify that GluN2B subunit is more abundant in extrasynaptic fractions [9, 10]. Furthermore, knocking out the GluN2B subunit in principal cortical neurons of mouse occludes ketamine’s antidepressant actions [11]. Meanwhile, GluN2B-selective antagonists produce antidepressant effects in rodent models of depression [12] and improve clinical symptoms of patients with depression [13]. The above results suggest that GluN2B receptors are essential for ketamine’s antidepressant effects, yet the upstream and downstream signaling involved in GluN2B remains unclear.

CaMKIIα is activated when calcium ions enter the cell via various ion channels on the membrane and the activation of CaMKIIα ultimately promotes autophosphorylation at threonine 286 (p-CaMKIIα), which binds to GluN2B and phosphorylates GluN2B at the S1303 site (p-GluN2B) [14, 15]. The synaptic binding of CaMKIIα/GluN2B has been intensively studied [16], and the interaction between GluN2B and CaMKIIα is important for synaptic CaMKIIα localization and activity [14, 17]. However, the role of extrasynaptic CaMKIIα and GluN2B in the antidepressant effects of ketamine has not been intensively investigated. Hence, in this study, we investigated the role of changes in extrasynaptic CaMKIIα and GluN2B, as well as the interaction between CaMKIIα and GluN2B, in the antidepressant effects of ketamine using an LPS-induced depression model.

Materials and methods

Animals

Male adult C57BL/6J mice (25–30 g) were purchased from the Model Animal Research Center (MARC) of Nanjing University, Nanjing, China. Four to five individuals were placed in each cage, and the mice were housed in a room temperature of 23 ± 1 °C, with a 12-h light/dark cycle. The mice were free to food and water. All animal experiments and related operations were carried out in accordance with the Guideline for the Care and Use of Laboratory Animals from the National Institutes of Health, USA.

LPS-induced depression model

In this experiment, the dose of LPS (1 mg/kg) was intraperitoneally (i.p.) injected based on one previous study [18]. LPS was dissolved in physiological saline and then injected at a volume of 10 ml/kg in all conditions. The solution is ready for use and injection of LPS was scheduled at a fixed time (09:00 and 10:00 a.m.).

Experimental design and drug administration

Experiment 1

Mice were randomly numbered and then divided into 4 groups: the Sal + Sal group, the LPS + Sal group, the Sal + Ket group, or the LPS + Ket group. First, LPS (1 mg/kg) or an equal volume of physiological saline was injected i.p. between 09:00 and 10:00 a.m. After 23.5 h, ketamine (10 mg/kg) or an equal volume of physiological saline was injected i.p. The open-field test (OFT), novelty-suppressed feeding test (NSFT), forced swim test (FST), body weight, and fur coat state of mice were evaluated 0.5 h after ketamine administration. In each group of mice, half of the animals underwent behavioral tests and the other half subjected to biochemical tests. The flow chart of experiment 1 is shown in Fig. 1a.

Fig. 1
figure1

Timeline of drug injection, behavioral test, and tissue collection: experiment 1 (a) and experiment 2 (b). BW, body weight; DMSO, dimethyl sulfoxide; FST, forced-swimming test; KN93, C26H29ClN2O4S.H3O4P; LPS, lipopolysaccharide; NSFT, novelty-suppressed feeding test; OFT, open-field test

Full size image

Experiment 2

Mice were randomly numbered and then divided into 4 groups: the Sal + dimethyl sulfoxide (DMSO) group, the LPS +DMSO group, the Sal + KN93 group, or the LPS + KN93 group. First, LPS (1 mg/kg) or an equal volume of physiological saline was injected i.p. between 09:00 and 10:00 a.m. After 23.5 h, KN93 (10 mg/kg) or an equal volume of DMSO was injected i.p. The selected dose of KN93 in this experiment is based on the pre-experiment results. The NSFT and FST were performed 0.5 h after KN93 administration. In each group of mice, half of the animals underwent behavioral tests and the other half subjected to biochemical tests. The flow chart of experiment 2 is shown in Fig. 1b.

Both ketamine hydrochloride (Gutian Pharmaceutical Company, China) and LPS (L-2880, Sigma, USA) were dissolved in physiological saline. KN93 (S7423, Selleckchem, USA) was dissolved in 1% DMSO.

Behavioral tests

Behavioral experiments are carried out in quiet rooms using an XR-XZ301 instrument (Xinruan Corporation, Shanghai, China). All behavioral data were analyzed by a researcher blinded to the experimental grouping.

Open-field test

Mice were placed in a white experimental box (40 cm × 40 cm × 40 cm; length × width × height) and allowed to move freely for 5 min. The entire process was automatically tracked by a camera placed above the experimental box. The total distance traveled was considered to be a measure of the ability of the mouse to move. The time spent in the center and the number of entries into the center were considered to be a measure of the level of anxiety in mice. At the end of each test, wipe the instrument with 75% alcohol to avoid the effect of the residual odor of the previous animal on the test results.

Novelty-suppressed feeding test

The mice were fasted 12 h before the experiment and the drinking water was not limited [19]. Before the experiment, two pieces of chow were placed in the center of a plastic box (40 cm × 40 cm × 40 cm; length × width × height). Then, mice were placed in the test box and allowed to move freely for 10 min. The time required for the mouse to enter the box to eat food for the first time is the feeding latency. The feeding latency was considered to be a measure of the level of depression in mice. At the end of the experiment, mice were placed in a cage with pre-weighed food, and the consumption of this food was recorded for 15 min.

Forced-swimming test

Mice were placed in a glass container (18-cm diameter × 28-cm height) of water (15 cm; 25 ± 1 °C) and allowed to swim under normal light for 6 min and recorded the total immobility time of the last 4 min [20]. The definition of immobility time refers to the time when the mouse passively floated with no additional activity or with no other movements except those to maintain balance in the water. After the experiment, the mouse body was wiped dry with absorbent paper and placed back in the original cage. Replace the water at the end of each test.

Physiological changes

The body weight change was monitored. For fur coat state, seven different body parts were evaluated: head, neck, dorsal and ventral coat, tail, forepaws, and hindpaws. For each area, a health state was noted 3 and damaged state with piloerection and/or dirty fur was noted 1. Intermediate state was noted 2. The total score of the coat state is the average of scores from the above seven body parts [21].

Western blot analysis

Tissue preparation and subcellular fractionation

The levels of p-CaMKIIα, CaMKIIα, p-GluN2B, and GluN2B in the synaptic and extrasynaptic fractions of the hippocampus were assessed by western blotting. The separation methods of the synaptic and extrasynaptic fractions refer to previous studies [22]. Briefly, the hippocampus of adult mice was dissected and homogenized in an ice-cold sucrose buffer (in mM): 320 sucrose, 10 Tris (pH 7.4), 1 EDTA, 1 Na3VO4, 5 NaF, 1 EGTA, and 1× protease inhibitor cocktail, and then centrifuged at 1000×g for 10 min at 4 °C. The supernatant (S1) was collected and centrifuged at 10,000×g for 20 min at 4 °C. Then, the pellet (P2) was saved and resuspended in sucrose buffer. Then, the pellet (P2) was centrifuged at 10,000×g for 20 min at 4 °C and repeated twice. Then, the pellet (P2) was resuspended in an ice-cold Triton X-100 buffer (in mM): 10 Tris (pH 7.4), 1 EDTA, 1 Na3VO4, 5 NaF, 1 EGTA, and 0.5 % Triton X-100. This pellet (P2) was rotated slowly 20 min at 4 °C. Then, the pellet (P2) was centrifuged at 32,000×g for 20 min at 4 °C. The supernatant and pellet comprised the extrasynaptic fraction (non-PSD) and synaptic fraction (PSD), respectively. The separation of the synaptic and extrasynaptic fraction was demonstrated by the distribution of postsynaptic density-95 (PSD95) and synaptophysin. The protein concentration of the four groups was measured by bicinchoninic acid (BCA) protein assay and then adjusted to the same level.

Total protein preparation

The levels of p-CREB, CREB, and BDNF in the total protein of the hippocampus were assessed by western blotting. Briefly, the hippocampus of adult mice was harvested on the ice and then homogenized in an ice-cold protein lysis buffer (in mM): 150 NaCl, 50 Tris-HCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 1 NaF, 1 Na3VO4, 1 PMSF, and 1× protease inhibitor cocktail. The homogenate was centrifuged at 10,000 rpm for 10 min at 4 °C. Then, the protein concentration of the four groups was measured by BCA protein assay and then adjusted to the same level.

Synaptosome preparation

The levels of GluR1 and GluR2 in the synaptosome of the hippocampus were assessed by western blotting. The separation methods of the synaptosome fractions refer to previous studies [23]. Briefly, the hippocampus of adult mice was harvested on the ice and then homogenized in an ice-cold sucrose solution (in mM): 320 sucrose, 20 HEPES (pH 7.4), 1 Na3VO4, 1 EDTA, 5 NaF, and 1× protease inhibitor cocktail, and then centrifuged at 2800 rpm for 10 min at 4 °C. The supernatant was collected and centrifuged at 12,000 rpm for 10 min at 4 °C. Then, the pellet (synaptosome fraction) was saved and resuspended in an ice-cold protein lysis buffer (in mM): 150 NaCl, 50 Tris-HCl (pH 7.4), 1% Triton X-100, 0.1% SDS, 1 Na3VO4, 2 EDTA, 5 NaF, and 1× protease inhibitor cocktail. The protein concentration of the four groups was measured by BCA protein assay and then adjusted to the same level.

Protein (10-20 μg/well) were separated by 8–12% SDS-PAGE gels and then transferred to polyvinylidene fluoride membranes. Five percent non-fat milk was used to incubate the membranes for 2 h at room temperature. After this, the membranes were incubated primary antibody overnight at 4 °C. The selected primary antibody is as follows: anti-BDNF (Abcam, Cambridge, UK), anti-CaMKIIα (phospho-T286) (Abcam, Cambridge, UK), anti-CaMKIIα (Abcam, Cambridge, UK), anti-CaMKIIβ (Abcam, Cambridge, UK), anti-CREB (Cell Signaling, MA, USA), anti-GAPDH (ProteinTech, USA), anti-β-actin (GeneTex, USA), anti-PSD95 (Millipore, MA, USA), anti-synaptophysin (Millipore, MA, USA), anti-NMDAR2B (phospho-S1303) (Abcam, Cambridge, UK), anti-Glutamate Receptor 1 (Abcam, Cambridge, UK), anti-NMDAR2B (Abcam, Cambridge, UK), anti-p-CREB (Cell Signaling, MA, USA), and anti-Glutamate Receptor 2 (Abcam, Cambridge, UK). The membranes were washed three times in TBST and then incubated in the corresponding secondary antibody (goat anti-rabbit or mouse and rabbit anti-goat; Bioworld Technology, MN, USA) for 2 h at room temperature. Finally, the protein bands were visualized by chemiluminescence method. The mean gray value of each protein band was quantified by Image J (NIH, Bethesda, MD, USA).

Immunofluorescence

Mice were anesthetized with 1% sodium pentobarbital (50 mg/kg, i.p.; Sigma, USA), followed by systemic perfusion of the mice via the left ventricle using physiological saline and 4% PFA. Then, the whole brain of the mice was taken out and dipped in 4% PFA for 4–6 h at 4 °C. After that, the brain was dehydrated in 20% and 30% sucrose at 4 °C, respectively. OCT was used to embed the brain when it sinks to the bottom. A 10-μm-thick coronal sections of the hippocampus were cut and immediately adhered to the slide. The slides were immersed in the PBS for 10 min to wash away the OCT during embedding. Next, the slides were blocked with 10% goat serum for 2 h at room temperature. After that, slides were incubated in primary antibodies diluted with 5% BSA overnight at 4 °C: anti-NMDAR2B (phospho-S1303) (Abcam, Cambridge, UK), anti-NMDAR2B (Abcam, Cambridge, UK), and anti-PSD95 (Millipore, MA, USA). The slides were washed with PBS (with 5 ‰ Triton X-100) for 3 × 5 min. Then, the slides were incubated in corresponding secondary antibodies (Alexa Fluor 488/549 goat anti-rabbit or mouse; Bioworld Technology, MN, USA) for 2 h at room temperature. After washing with PBS (with 5 ‰ Triton X-100) for 3 × 5 min, the slides were incubated with DAPI to label nuclei. A confocal scanning microscope (Carl Zeiss, LSM880, Germany) was used to obtain the fluorescence images of the region of interest. The Pearson’s coefficient colocalization was used to quantify the colocalization of two confocal immunofluorescences, which was calculated by a plug-in package in Image J (NIH, Bethesda, MD, USA).

Immunoprecipitation

Immunoprecipitation was used to detect the interaction between p-CaMKIIα and GluN2B. Immunoprecipitation from the extrasynaptic fractions of the hippocampus was performed with rabbit NMDAR2B (2–3 μg) antibody [24]. Briefly, the extrasynaptic fractions of the hippocampus were obtained as described above. The extracts were precleared by adding nonspecific control immunoglobulin G (1 μg) and 20 μl of Protein G Sepharose (Sigma, USA). The supernatant was collected and incubated with nonspecific IgG (2 μg) or rabbit anti-NMDAR2B (2 μg; Abcam, Cambridge, UK) overnight at 4 °C. The next day, they were mixed with the addition of 40 μl of Protein G Sepharose (Sigma, USA) and then rotated slowly for 4 h at 4 °C. After that, the beads were washed three times in buffer A (in mM): 150 NaCl, 50 Tris-HCl, 0.1% Triton X-100, and 1 EDTA. Then, the beads were washed three times in buffer B (in mM): 300 NaCl, 50 Tris-HCl, 0.1% Triton X-100, and 1 EDTA. Finally, the beads were denatured in SDS buffer and separated by SDS-PAGE.

Primary hippocampal neuron cultures

Primary hippocampal neurons were prepared and processed as described previously with minor modifications [25]. The hippocampus from postnatal (P0-P1) C57BL/6 mice were rapidly and aseptically dissected in ice-cold DMEM medium, followed by removal of meninges and mincing into small pieces. The hippocampal tissue was then digested in 0.25% trypsin for 15 min at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. The hippocampal tissue was washed twice with DMEM medium (including FBS, F12); then, the tissue was gently blown (not more than 30 times) and then allowed to stand for 10 min. The supernatant was gently resuspended in culture medium and plated at 40,000–50,000 cells per cm2 on Poly-l-lysine-coated (Sigma-Aldrich). Every 3 days, half of the medium was replaced with freshly prepared medium.

Primary neuron transfection and siRNA

Hippocampal neurons were transfected at DIV10 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommendations. For CaMKIIα knockdown, cells were transfected with 50 nM CaMKIIα siRNA for 24 h. Control siRNA and CaMKIIα siRNA (R10043.8) were from Guangzhou RiboBio Co., Ltd. The culture treatments were conducted 24 h after transfection.

Immunoblotting and immunocytochemistry

For cell western blotting assays, hippocampal neurons were washed gently with PBS for three times and then harvested in an ice-cold protein lysis buffer (in mM): 150 NaCl, 50 Tris-HCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 1 NaF, 1 Na3VO4, 1 PMSF, and 1× protease inhibitor cocktail. The homogenate was centrifuged at 10,000 rpm for 10 min at 4 °C. Then, the protein concentration was measured by BCA protein assay and then adjusted to the same level. The rest of the operations are the same as tissue western blotting assays.

Hippocampal neurons were fixed with a 4% PFA/4% sucrose mixture in PBS that was preheated to 37 °C in advance for 10 min at room temperature. The neurons were then permeabilized with 0.1% (vol/vol) Triton X-100 in PBS for 10 min at room temperature and washed gently with PBS for three times. The neurons were blocked with ready-to-use normal goat serum for 1 h at room temperature and subsequently incubated at 4 °C overnight with primary antibodies. The primary antibodies used were anti-CaMKIIα (Abcam, Cambridge, UK) and anti-NMDAR2B (Abcam, Cambridge, UK).

After washing with PBS for 3 × 5 min, the neurons were exposed to the secondary antibodies Alexa fluor 488/549 goat anti-rabbit (1:100; Bioworld Technology, St. Louis Park, MN, USA), and DAPI to label nuclei (1:1000; Sigma, St. Louis, MO, USA) for 2 h at room temperature. Fluorescence images were obtained by confocal scanning microscopy (Carl Zeiss, LSM880, Germany). Numbers of GluN2B puncta as well as the mean intensity of fluorescent signals (CaMKIIα and GluN2B) in individual neurons were measured using the Image J function “Analyze > measure.”

Electrophysiological recording

The mice were anesthetized and the whole brain was taken out on the ice. The brain was quickly dipped in a pre-oxygenated (95% O2/5% CO2) cutting solution (in mM): 2.6 KCl, 1.25 NaH2PO4, 26 NaHCO3, 0.5 CaCl2, 5 MgCl2, 212 sucrose and 10 dextrose for 2 min. In the cutting solution, a 300-μm-thick coronal slices of the hippocampus were cut out. Then, the slices were immediately transferred to the artificial cerebrospinal fluid (ACSF) (in mM): 124 NaCl, 5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 2 MgCl2, and 10 dextrose for incubation. The hippocampal slices were then kept at 26 °C for 1 h before recording. In order to induce LTP, concentric bipolar tungsten electrodes and the recording pipettes were placed in the Schaffer collateral–commissural fibers and the stratum radiatum of hippocampal CA1 region, respectively. During the recording period, ACSF was perfused continuously and the picrotoxin (0.1 mM) and APV (80 μM) were added to the ASCF to block GABAA and NMDA receptors, respectively. In this study, LTP was evoked by high-frequency stimulation (HFS; three trains of 100 Hz with a 10-s interval between each train). A steady baseline was recorded for at least 10 min before the induction of LTP. The field excitatory postsynaptic potential (fEPSP) slope between 10% and 90% was used to indicate the fEPSP magnitude. Data are normalized to mean baseline value and shown as mean ± S.E.M. Slices were considered to demonstrate LTP if the amplitude of the fEPSP was increased by at least 15% compared to baseline. The signal was amplified with pClamp 700B amplifier (Axon Instruments, Foster City, CA), acquired at 10 kHz and filtered at 2 kHz.

Statistical analysis

Data are shown as mean ± SEM. SPSS software (version 25.0, IL, USA) and GraphPad Prism (version 7, CA, USA) were used for statistical analyses. For comparisons of two groups, the two-tailed unpaired t test was used for statistical analysis. For three or more groups of samples, Shapiro–Wilk test and Levene’s test were used for the distribution and variance analysis of the data. When data were not normally distributed, the differences among groups were compared by Kruskal–Wallis one-way ANOVA followed by Bonferroni’s correction. When data were normally distributed, the differences among groups were compared by two-way ANOVA followed by Bonferroni’s multiple comparisons test. LPS injection and ketamine or KN93 administration were considered two independent factors. P < 0.05 indicates that the difference is statistically significant.

Results

Ketamine improved LPS-induced depression-like behaviors

In the OFT, no significant difference in the total traveled distance within 5 min was observed in the four groups, indicating that LPS injection and ketamine administration did not affect the locomotor activity of mice (Fig. 2a; interaction: LPS × ketamine, F1,24 = 2.54, P > 0.05; LPS: F1,24 = 3.735, P > 0.05; ketamine: F1,24 = 3.663, P > 0.05; LPS is LPS + Sal vs Sal + Sal; ketamine is LPS + Ket vs LPS + Sal). LPS injection decreased the time spent in the center (interaction: LPS × ketamine, F1,24 = 4.40, P < 0.05; LPS: F1,24 = 8.869, P < 0.01; ketamine: F1,24 = 20.273, P < 0.01) and the number of entries into the center (interaction: LPS × ketamine; F1,24 = 18.253, P < 0.05; LPS: F1,24 = 5.116, P < 0.05; ketamine: F1,24 = 18.253, P < 0.01), both of these effects were rapidly reversed by ketamine administration (Fig. 2b). In the FST, LPS injection increased the immobility time, which was reversed by ketamine administration (Fig. 2c; interaction: LPS × ketamine, F1,24 = 15.13, P < 0.05; LPS: F1,24 = 13.414, P < 0.01; ketamine: F1,24 = 22.327, P < 0.01). In the NSFT, ketamine administration reversed LPS-induced increase in the feeding latency (interaction: LPS × ketamine, F1,24 = 21.226, P < 0.05; LPS: F1,24 = 30.552, P < 0.01; ketamine: F1,24 = 30.165, P < 0.01), and the total food consumption (interaction: LPS × ketamine, F1,24 = 1.126, P > 0.05; LPS: F1,24 = 4.504, P > 0.05; ketamine: F1,24 = 0.681, P > 0.05) in the four groups were not affected (Fig. 2d). Ketamine administration did not affect LPS-induced decrease in body weight change in the mice (Fig. 2e; interaction: LPS × ketamine, F1,32 = 0.871, P > 0.05; LPS: F1,32 = 0.959, P < 0.01; ketamine: F1,32 = 17.855, P > 0.05). LPS induced a poor coat state (indicated by a decreased score) in mice that was attenuated by ketamine administration (Fig. 2f; interaction: LPS × ketamine, F1,24 = 7.360, P > 0.05; LPS: F1,24 = 21.630, P < 0.01; ketamine: F1,24 = 19.293, P < 0.01). In summary, these behavioral results indicated that ketamine (10 mg/kg) administration can eliminate the depression and anxious-like behaviors caused by LPS injection without affecting the locomotor activity of mice.

Fig. 2
figure2

Ketamine administration rescued LPS-induced depression-like behaviors. a In OFT, there was no significant difference in total distance within 5 min among the four groups. b In the OFT, ketamine administration prevented LPS-induced decrease in time spent in the center and the number of entries into the center. c In the NSFT, ketamine administration prevented LPS-induced increase in feeding latency, and the total food consumption was not different among the four groups. d In the FST, ketamine administration prevented LPS-induced increase in immobility time. e Ketamine administration did not affect LPS-induced decrease in body weight change in the mice. f Ketamine administration improved the poor coat state of mice induced by LPS. Data are presented as mean ± SEM (n = 7–10 mice per group). *p < 0.05, **p < 0.01 vs the Sal + Sal group; ##p < 0.01 vs the LPS + Sal group. Sal, saline

Full size image

Ketamine reversed LPS-induced extrasynaptic CaMKIIα activity in the hippocampus

In the extrasynaptic fractions of the hippocampus, ketamine administration reversed the elevated level of p-CaMKIIα induced by LPS injection (Fig. 3a; interaction: LPS × ketamine, F1,12 = 11.495, P < 0.05; LPS: F1,12 = 5.710, P < 0.05; ketamine: F1,12 = 5.604, P < 0.05). In the synaptic fractions of the hippocampus, no significant difference in the level of p-CaMKIIα was observed in the four groups (Fig. 3b; interaction: LPS × ketamine, F1,12 = 0.426, P > 0.05; LPS: F1,12 = 0.000, P > 0.05; ketamine: F1,12 = 0.015, P > 0.05).

Fig. 3
figure3

Ketamine reversed LPS-induced extrasynaptic CaMKIIα activity in the hippocampus. The levels of CaMKIIα and p-CaMKIIα in extrasynaptic and synaptic fractions of the hippocampus were determined by western blotting. a Ketamine administration reversed LPS-induced increase in extrasynaptic p-CaMKIIα level in the hippocampus. b There was no significant difference in synaptic p-CaMKIIα level in the hippocampus among the four groups. Data are presented as mean ± SEM (n = 4–6 mice per group). *p < 0.05 vs the Sal + Sal group; #p < 0.05 vs the LPS + Sal group

Full size image

Ketamine reversed LPS-mediated extrasynaptic GluN2B localization and phosphorylation in the hippocampus

In the extrasynaptic fractions, ketamine administration reversed LPS-induced increase in the level of GluN2B (Fig. 4a; interaction: LPS × ketamine, F1,12 = 3.267, P > 0.05; LPS: F1,12 = 7.045, P < 0.05; ketamine: F1,12 = 5.224, P < 0.05). In the synaptic fractions, no significant difference in GluN2B level was observed in the four groups (Fig. 4a; interaction: LPS × ketamine, F1,12 = 0.172, P > 0.05; LPS: F1,12 = 0.020, P > 0.05; ketamine: F1,12 = 0.775, P > 0.05). Next, to confirm this finding, dual antibody labeling of surface GluN2B (an antibody that specifically binds to the N-terminal of the GluN2B) and synapse-specific protein PSD95 was used to identify synaptic GluN2B localization. In the CA1, CA3, and DG of the hippocampus, no significant difference in GluN2B/PSD95 colocalization was observed in the four groups (Fig. 4e; CA1: interaction: LPS × ketamine, F1,20 = 0.109, P > 0.05; LPS: F1,20 = 0.981, P > 0.05; ketamine: F1,20 = 0.303, P > 0.05; CA3: interaction: LPS × ketamine, F1,20 = 2.381, P > 0.05; LPS: F1,20 = 0.000, P > 0.05; ketamine: F1,20 = 0.381, P > 0.05; DG: interaction: LPS × ketamine, F1,20 = 0.000, P > 0.05; LPS: F1,20 = 0.155, P > 0.05; ketamine: F1,20 = 0.843, P > 0.05). This result suggests that ketamine did not affect synaptic GluN2B localization. In the CA1 and DG of the hippocampus, ketamine administration reversed LPS-induced increase in GluN2B immunoreactivity (Fig. 4f; CA1: interaction: LPS × ketamine, F1,12 = 17.929, P < 0.05; LPS: F1,12 = 16.714, P < 0.01; ketamine: F1,12 = 14.044, P < 0.01; DG: interaction: LPS × ketamine, F1,12 = 33.842, P < 0.05; LPS: F1,12 = 52.299, P < 0.01; ketamine: F1,20 = 30.386, P < 0.01). Combined with the above results and given that ketamine administration did not affect synaptic GluN2B localization, this result suggests that the ketamine-mediated reduction in GluN2B mainly affects extrasynaptic fractions. In the extrasynaptic fractions, ketamine administration reversed LPS-induced increase in the level of p-GluN2B (Fig. 4b; LPS: H = 8.824, P < 0.05; ketamine: H = 8.824, P < 0.05). In the synaptic fractions, no significant difference in p-GluN2B level was observed in the four groups (Fig. 4b; interaction: LPS × ketamine, F1,12 = 0. 144, P > 0.05; LPS: F1,12 = 0.700, P > 0.05; ketamine: F1,12 = 0.096, P > 0.05). In the CA1, CA3, and DG of the hippocampus, no significant difference in p-GluN2B/PSD95 colocalization was observed in the four groups (Fig. 4g; CA1: interaction: LPS × ketamine, F1,20 = 0.773, P > 0.05; LPS: F1,20 = 0.057, P > 0.05; ketamine: F1,20 = 0.313, P > 0.05; CA3: interaction: LPS × ketamine, F1,20 = 2.381, P > 0.05; LPS: F1,20 = 0.000, P > 0.05; ketamine: F1,20 = 0.381, P > 0.05; DG: interaction: LPS × ketamine, F1,20 = 0.356, P > 0.05; LPS: F1,20 = 0.181, P > 0.05; ketamine: F1,20 = 0.007, P > 0.05). In the CA1 and DG of the hippocampus, ketamine administration reversed LPS-induced increase in p-GluN2B immunoreactivity (Fig. 4 h; CA1: interaction: LPS × ketamine, F1,12 = 21.120, P < 0.05; LPS: F1,12 = 12.588, P < 0.01; ketamine: F1,12 = 11.595, P < 0.01; DG: interaction: LPS × ketamine, F1,12 = 15.625, P < 0.05; LPS: F1,12 = 52.299, P < 0.01; ketamine: F1,20 = 10.632, P < 0.01). This result also suggests that the ketamine-induced reduction in p-GluN2B mainly affects extrasynaptic fractions. In summary, these results indicate that downregulation of GluN2B and p-GluN2B induced by ketamine is mainly derived from the extrasynaptic fractions of the hippocampus.

Fig. 4
figure4

Ketamine reversed LPS-induced increase in extrasynaptic GluN2B localization and phosphorylation in the hippocampus. The levels of GluN2B and p-GluN2B in extrasynaptic and synaptic fractions of the hippocampus were determined by western blotting and immunofluorescence. a Ketamine administration reversed LPS-induced increase in extrasynaptic GluN2B level but did not affect synaptic GluN2B level in the hippocampus. b Ketamine administration reversed LPS-induced increase in extrasynaptic p-GluN2B level but did not affect synaptic p-GluN2B level in the hippocampus. c Immunofluorescent images show the colocalization of PSD95 (red) and surface GluN2B receptor (green) in CA1 regions of the hippocampus. Arrow indicates colocalization, and triangle indicates no colocalization. d Immunofluorescent images show the colocalization of PSD95 (red) and p-GluN2B (green) in CA1 regions of the hippocampus. Arrow indicates colocalization, and triangle indicates no colocalization. e Pearson’s correlation coefficient of PSD95 and GluN2B was not significantly different among the four groups in CA1, CA3, and DG of the hippocampus. f Ketamine administration reversed LPS-induced increase in GluN2B immunoreactivity in CA1 and DG of the hippocampus. g Pearson’s correlation coefficient of PSD95 and p-GluN2B was not significantly different among the four groups in CA1, CA3, and DG of the hippocampus. h Ketamine administration reversed LPS-induced increase in p-GluN2B immunoreactivity in CA1 and DG of the hippocampus. Scale bars indicate 20 μm. Data are presented as mean ± SEM (n = 4–6 mice per group). *p < 0.05, **p < 0.01 vs the Sal + Sal group; #p < 0.05, ##p < 0.01 vs the LPS + Sal group

Full size image

Ketamine reversed LPS-induced enhancement of the extrasynaptic interaction of p-CaMKIIα–GluN2B in the hippocampus

A GluN2B antibody was used to precipitate the NMDA receptors complex from the extrasynaptic fractions of the hippocampus. Immunoprecipitation assays revealed that p-CaMKIIα binds GluN2B receptors in the extrasynaptic fractions of the hippocampus (Fig. 5a). In addition, ketamine administration attenuated the enhancement of the interaction between p-CaMKIIα (interaction: LPS × ketamine, F1,12 = 8.372, P < 0.05; LPS: F1,12 = 8.207, P < 0.05; ketamine: F1,12 = 16.954, P < 0.01) and GluN2B (interaction: LPS × ketamine, F1,12 = 3.117, P > 0.05; LPS: F1,12 = 5.341, P < 0.05; ketamine: F1,12 = 9.571, P < 0.01) induced by LPS (Fig. 5b). These results showed that CaMKIIα was an important binding partner for GluN2B. These results were confirmed by CaMKIIα loss of function assays using siRNA. In cultured hippocampal neurons, after transfection with control siRNA and CaMKIIα siRNA, the efficiency of knocking down was evaluated by western blotting (Fig. 5e; t = 3.571, P < 0.05) and immunocytochemistry (Fig. 5g; t = 5.831, P < 0.0001). CaMKIIα siRNA reduced enzyme levels by about 30% (Fig. 5e, g). CaMKIIα siRNA decreased the level (Fig. 5d; t = 3.112, P < 0.05) and the number and fluorescence intensity of GluN2B puncta (Fig. 5i; U = 16, P < 0.0001; t = 2.516, P < 0.05) in the cultured hippocampal neurons. Taken together, these data suggest that the level and number of clusters of GluN2B were regulated by CaMKIIα signal.

Fig. 5
figure5

Ketamine reversed the enhanced extrasynaptic p-CaMKIIα–GluN2B interaction in the hippocampus induced by LPS. a Immunoprecipitation of GluN2B with p-CaMKIIα and CaMKIIβ in extrasynaptic fractions of the hippocampus. b Ketamine administration attenuated the enhanced interaction between p-CaMKIIα and GluN2B induced by LPS. c The levels of CaMKIIα and GluN2B in the DIV11 hippocampal neurons after transfection with control siRNA and CaMKIIα siRNA were determined by western blotting. d CaMKIIα siRNA decreased GluN2B level in the hippocampal neurons. e CaMKIIα siRNA decreased CaMKIIα level in the hippocampal neurons. f DIV10 hippocampal neurons were transfected with control siRNA and CaMKIIα siRNA, fixed on DIV11, and immunostained with antibodies to CaMKIIα. Shown are representative confocal images of transfected neurons. g CaMKIIα siRNA decreased the mean intensity of CaMKIIα signals in the cell body and dendrites in f. h DIV10 hippocampal neurons were transfected with control siRNA and CaMKIIα siRNA, fixed on DIV11, and immunostained with antibodies to GluN2B. Shown are representative confocal images of transfected neurons. i CaMKIIα siRNA decreased the mean intensity of GluN2B signals in the cell body and dendrite and the GluN2B puncta per 100 μm dendrite length in (h). Scale bars indicate 20 μm. Data are presented as mean ± SEM (n = 4–6 mice per group or n = 60 neurons). *p < 0.05 vs the Sal + Sal group; ##p < 0.01 vs the LPS + Sal group; &p < 0.05, &&&&p < 0.0001 vs the control siRNA group

Full size image

Inhibition of CaMKIIα by KN93 prevented depression-like behaviors and reduced elevated extrasynaptic GluN2B localization and phosphorylation in the hippocampus induced by LPS

To further determine the relationship between the activation of CaMKIIα and GluN2B in vivo, an inhibitor of CaMKIIα, KN93, was used in the present study. In the NSFT, KN93 treatment prevented LPS-induced increase in feeding latency (interaction: LPS × KN93, F1,24 = 30.107, P < 0.01; LPS: F1,24 = 33.146, P < 0.01; KN93: F1,24 = 21.992, P < 0.01; LPS is LPS + DMSO versus Sal + DMSO; KN93 is LPS + KN93 versus LPS + DMSO), and the total food consumption in the four groups were not affected (Fig. 6a; interaction: LPS × KN93, F1,24 = 0.255, P > 0.05; LPS: F1,24 = 0.954, P > 0.05; KN93: F1,24 = 0.085, P > 0.05). Moreover, KN93 treatment prevented LPS-induced increase in immobility time in the FST (Fig. 6b; interaction: LPS × KN93, F1,24 = 22.909, P < 0.01; LPS: F1,24 = 13.584, P < 0.01; KN93: F1,24 = 5.873, P < 0.05). These behavioral results suggest that inhibition of CaMKIIα by KN93 results in an antidepressant phenotype. Furthermore, in the extrasynaptic fractions of the hippocampus, KN93 treatment prevented the increase in p-CaMKIIα levels induced by LPS (Fig. 6c; interaction: LPS × KN93, F1,22 = 5.312, P < 0.05; LPS: F1,22 = 4.039, P < 0.05; KN93: F1,22 = 15.795, P < 0.01). In the extrasynaptic fractions of the hippocampus, KN93 treatment prevented the increase in GluN2B level induced by LPS (Fig. 6d; interaction: LPS × KN93, F1,25 = 22.571, P < 0.05; LPS: F1,25 = 6.001, P < 0.05; KN93: F1,25 = 8.058, P < 0.01). In the synaptic fractions, no significant difference in GluN2B level was observed in the four groups (Fig. 6d; interaction: LPS × KN93, F1,12 = 0.002, P > 0.05; LPS: F1,12 = 3.494, P > 0.05; KN93: F1,12 = 0.428, P > 0.05). In the CA1, CA3, and DG of the hippocampus, no significant difference in GluN2B/PSD95 colocalization was observed in the four groups (Fig. 6 h; CA1: interaction: LPS × KN93, F1,20 = 3.375, P > 0.05; LPS: F1,20 = 1.042, P > 0.05; KN93: F1,20 = 0.042, P > 0.05; CA3: interaction: LPS × KN93, F1,20 = 0.632, P > 0.05; LPS: F1,20 = 0.632, P > 0.05; KN93: F1,20 = 0.040, P > 0.05; DG: interaction: LPS × KN93, F1,20 = 0.000, P > 0.05; LPS: F1,20 = 0.032, P > 0.05; KN93: F1,20 = 0.289, P > 0.05). In the CA1, CA3, and DG of the hippocampus, KN93 treatment reversed LPS-induced increased in GluN2B immunoreactivity (Fig. 6i; CA1: interaction: LPS × KN93, F1,12 = 21.889, P < 0.05; LPS: F1,12 = 12.144, P < 0.01; KN93: F1,20 = 15.884, P < 0.01; CA3: interaction: LPS × KN93, F1,12 = 8.833, P < 0.05; LPS: F1,12 = 13.404, P < 0.01; KN93: F1,20 = 16.046, P < 0.01; DG: interaction: LPS × KN93, F1,12 = 8.870, P < 0.05; LPS: F1,12 = 18.344, P < 0.01; KN93: F1,20 = 13.806, P < 0.01). In the extrasynaptic fractions, KN93 treatment reversed LPS-induced increased in p-GluN2B level (Fig. 6e; interaction: LPS × KN93, F1.12 = 9.784, P < 0.05; LPS: F1,12 = 5.871, P < 0.05; KN93: F1,12 = 18.922, P < 0.01). In the synaptic fractions, no significant difference in p-GluN2B level was observed in the four groups (Fig. 6e; interaction: LPS × KN93, F1,12 = 0.194, P > 0.05; LPS: F1,12 = 1.157, P > 0.05; KN93: F1,12 = 0.258, P > 0.05). In the CA1, CA3, and DG of the hippocampus, no significant difference in p-GluN2B/PSD95 colocalization was observed in the four groups (Fig. 6j; CA1: interaction: LPS × KN93, F1,20 = 0.169, P > 0.05; LPS: F1,20 = 0.169, P > 0.05; KN93: F1,20 = 0.061, P > 0.05; CA3: interaction: LPS × KN93, F1,20 = 2.609, P > 0.05; LPS: F1,20 = 0.290, P > 0.05; KN93: F1,20 = 0.290, P > 0.05; DG: interaction: LPS × KN93, F1,20 = 0.016, P > 0.05; LPS: F1,20 = 0.16, P > 0.05; KN93: F1,20 = 0.016, P > 0.05). In the CA1 and DG of the hippocampus, KN93 treatment reversed LPS-induced increased in p-GluN2B immunoreactivity (Fig. 6 k; CA1: interaction: LPS × KN93, F1,12 = 3.688, P < 0.05; LPS: F1,12 = 5.904, P < 0.05; KN93: F1,20 = 6.328, P < 0.05; DG: interaction: LPS × KN93, F1,12 = 24.451, P < 0.05; LPS: F1,12 = 29.510, P < 0.01; KN93: F1,20 = 12.616, P < 0.01). In summary, these results indicate that CaMKIIα activation has an effect on the localization and phosphorylation of GluN2B in the extrasynaptic fraction of the hippocampus and is related to the rapid antidepressant effect of ketamine.

Fig. 6
figure6

Inhibition of CaMKIIα by KN93 prevented the depression-like behaviors and reduced the elevated extrasynaptic GluN2B localization and phosphorylation in the hippocampus induced by LPS. a KN93 treatment prevented LPS-induced increase in feeding latency in the NSFT, and the total food consumption was not different among the four groups. b KN93 treatment prevented LPS-induced increase in immobility time in the FST. c KN93 treatment reversed LPS-induced increase in extrasynaptic p-CaMKIIα level in the hippocampus. d KN93 treatment reversed LPS-induced increase in extrasynaptic GluN2B level but did not affect synaptic GluN2B level in the hippocampus. e KN93 treatment reversed LPS-induced increase in extrasynaptic p-GluN2B level but did not affect synaptic p-GluN2B level in the hippocampus. f Immunofluorescent images show the colocalization of PSD95 (red) and surface GluN2B receptor (green) in CA1 regions. Arrow indicates colocalization, and triangle indicates no colocalization. g Immunofluorescent images show the colocalization of PSD95 (red) with p-GluN2B (green) in CA1 regions. Arrow indicates colocalization, and triangle indicates no colocalization. h Pearson’s correlation coefficient of PSD95 and GluN2B was not significantly different among the four groups in CA1, CA3, and DG of the hippocampus. i KN93 treatment reversed LPS-induced increase in GluN2B immunoreactivity in CA1, CA3, and DG of the hippocampus. j Pearson’s correlation coefficient of PSD95 and p-GluN2B was not significantly different among the four groups in CA1, CA3, and DG of the hippocampus. k KN93 treatment reversed LPS-induced increase p-GluN2B immunoreactivity in CA1 and DG of the hippocampus. Scale bars indicate 20 μm. Data are presented as mean ± SEM (n = 4–10 mice per group). *p < 0.05, **p < 0.01 vs the Sal + DMSO group; #p < 0.05, ##p < 0.01vs the LPS + DMSO group

Full size image

Ketamine upregulated the expressions of p-CREB and BDNF and improved the synaptic dysfunction in the hippocampus

Ketamine administration blocked LPS-induced significantly decreased in p-CREB expression in the hippocampus (Fig. 7a; interaction: LPS × ketamine, F1,12 = 25.310, P < 0.05; LPS: F1,12 = 7.936, P < 0.05; ketamine: F1,12 = 6.672, P < 0.05). Ketamine administration blocked LPS-induced significantly decreased in BDNF expression in the hippocampus (Fig. 7b; interaction: LPS × ketamine, F1,12 = 22.039, P < 0.05; LPS: F1,12 = 6.525, P < 0.05; ketamine: F1,12 = 16.408, P < 0.01). Ketamine administration sufficiently prevented LPS-induced depression in SC-CA1 LTP of the hippocampus (interaction: LPS × ketamine, F1,8 = 10.706, P < 0.05; LPS: F1,8 = 7.476, P < 0.05; ketamine: F1,8 = 6.972, P < 0.05). Ketamine administration reversed the decrease in GluR1 level induced by LPS but did not affect GluR2 level (Fig. 7d, e; GluR1: interaction: LPS × ketamine, F1,12 = 21.165, P < 0.05; LPS: F1,12 = 4.478, P < 0.05; ketamine: F1,12 = 9.843, P < 0.01; GluR2: interaction: LPS × ketamine, F1,12 = 0.019, P > 0.05; LPS: F1,12 = 1.425, P > 0.05; ketamine: F1,12 = 0.010, P > 0.05).

Fig. 7
figure7

Ketamine reversed LPS-induced downregulation of p-CREB and BDNF expressions and the synaptic dysfunction in the hippocampus. a Ketamine administration blocked LPS-induced decrease in p-CREB expression in the hippocampus. b Ketamine administration blocked LPS-induced decrease in BDNF expression in the hippocampus. c Schematic representation of fEPSP before (gray) and after (black) HFS among the four groups. Horizontal calibration bars, 10 ms; vertical bars, 0.2 mV. Time course of fEPSP data normalized to the level of the 10-min baseline interval. Ketamine administration prevented LPS-induced depression of SC-CA1 LTP in the hippocampus. d, e Ketamine administration reversed LPS-induced decrease in GluR1 level but did not affect GluR2 level in the hippocampal synaptosomes. Data are presented as mean ± SEM (n = 4-7 mice per group). *p < 0.05 vs the Sal + Sal group; #p < 0.05, ##p < 0.01 vs the LPS + Sal group

Full size image

Discussion

In the present study, we found decreased extrasynaptic CaMKIIα activity and the resulting changes in extrasynaptic GluN2B localization and phosphorylation were associated with the antidepressant effects of ketamine. Furthermore, ketamine administration upregulated the expressions of p-CREB and BDNF in the hippocampus and prevented the impairment of LTP induction as well as the synaptic protein loss induced by LPS. Altogether, these results suggested that extrasynaptic CaMKIIα plays a key role in ketamine’s antidepressant effects by affecting extrasynaptic GluN2B localization and phosphorylation, and synaptic plasticity. Thus, we propose a model describing a possible pathway for extrasynaptic CaMKIIα to participate in the antidepressant mechanism of ketamine (see Fig. 8).

Fig. 8
figure8

Schematic diagram illustrates extrasynaptic CaMKIIα and GluN2B in the hippocampus are involved in the antidepressant process of ketamine. LPS stimulation induces extrasynaptic CaMKIIα phosphorylation (p-CaMKIIα) and then binding to extrasynaptic GluN2B in the hippocampus, which causes extrasynaptic GluN2B retention and phosphorylation. The activation of extrasynaptic GluN2B downregulates p-CREB and BDNF levels and subsequently impairs LTP induction as well as induces synaptic protein deficits in the hippocampus, ultimately leading to depression-like behaviors. Ketamine administration reverses extrasynaptic CaMKIIα activation, followed by the normalization of extrasynaptic GluN2B localization and phosphorylation, which increases p-CREB, BDNF, and GluR1 levels in the hippocampus, and finally rescues depression-like behaviors

Full size image

The prevalence of depression is higher in patients with immune disorders and infections, suggesting inflammation plays a key role in depression. For this reason, we established an animal model of depression by LPS injection, which has been well described in previous studies [26]. It has been reported that LPS at a dose of 0.83 mg/kg could successfully induce depression-like behaviors [27]. In our study, depression-like behaviors were induced by LPS (1 mg/kg) at 24 h after intraperitoneal injection, which were prevented by ketamine administration. Furthermore, LPS injection induced anxiety behaviors, which were also reversed by ketamine administration. Moreover, ketamine administration improved the deteriorating state of fur coat of mice induced by LPS. The latter is also a well-validated index of depression [28]. Similarly, a previous study reported that antidepressant CRF1 antagonist could counteract the deleterious effects of chronic unpredictable stress on coat state [29]. Taken together, our results further confirm prior observations of antidepressant and anti-anxiety effects of ketamine [30].

Neuroinflammation is considered as a risk factor for depression and also a marker of resistance to depression treatment [31, 32]. Increased levels of proinflammatory biomarkers (including CRP, IL-6, and TNF-α) were found in patients with depression [33, 34], whereas NSAIDs treatment significantly inhibited the inflammatory response and reduced the suicidal ideation and depression symptoms in depressed patients [35]. Similarly, ketamine administration has been shown to suppress the LPS-induced inflammatory response in human [36] or rats [37] and reduce suicidal symptoms and HDRS scores in depressed patients [38]. Furthermore, previous studies have shown that ketamine could alleviate LPS-induced depression-like behaviors, which were related to increased expressions of IL-1β and IL-6 and decreased expression of IL-10 in the rats [39]. Moreover, serum IL-6 is considered a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with depression [40]. In animal studies, it has been demonstrated that there is a close relation between microglia and synaptic plasticity. Microglia dynamically interact with synapses and participate in activity-dependent synaptic pruning and maturation [41]. In human studies, significant microgliosis is observed in depressed patients with suicide [42]. Classical antidepressants could inhibit microglial responses caused by inflammatory stimulus [43]. However, the mechanism by which inflammation induces depression remains unclear.

Accumulating evidence suggests that CaMKIIα is involved in the therapy for depression. Chronic fluoxetine treatment reduces the activation of CaMKIIα neurons in the mPFC, reversing the effect of poststroke depression [44]. The inhibition of CaMKIIα neurons in the lateral habenula underlies the antidepressant effects of light therapy [45]. Furthermore, intraperitoneal injection of TATCN21, an inhibitor of CaMKIIα, shows antidepressant phenotype in two classic depression-related behavioral tests [8]. Similarly, in the present study, ketamine administration reversed extrasynaptic CaMKIIα activation in the hippocampus. Moreover, a CaMKIIα inhibitor, KN93, also reversed extrasynaptic CaMKIIα activation and attenuated depression-like behaviors. Currently, no previous studies investigated the role of extrasynaptic CaMKIIα in LPS-induced depression-like behaviors and the antidepressant effect of ketamine. Most studies focus on the total level of CaMKIIα in different brain regions. Our results showed that changes in CaMKIIα activation were observed in extrasynaptic but not in the synaptic fraction. A recent study showed that xanthoceraside alleviated learning-memory deficits in APP/PS1 transgenic mice, and the mechanism is associated with increased expression of CaMKII in synaptic, but not extrasynaptic fraction [46]. In addition, previous studies have shown that the anxious-like behaviors in serotonin receptor 1a knockout mice are related to the increased phosphorylated CaMKIIα in extrasynaptic fraction of the hippocampus [47]. Although the function of extrasynaptic CaMKIIα is not fully understood, we speculated that increased phosphorylated CaMKIIα in extrasynaptic fraction of the hippocampus might contribute to LPS-induced depression-like behaviors.

The activation of extrasynaptic NMDARs has an important role in the etiology of depression [48]. Chronic unpredictable stress caused overactivation of extrasynaptic GluN2B in the mPFC and the GluN2B antagonist produced rapid antidepressant-like effects [24]. Moreover, blocking of extrasynaptic NMDA receptors is also involved in the antidepressant effects of ketamine by preventing ElF-2 phosphorylation and BDNF synthesis [49]. Similarly, in our study, ketamine administration reduced extrasynaptic GluN2B localization and phosphorylation in the hippocampus. Changes in GluN2B are observed in extrasynaptic, but not in the synaptic fraction. Indeed, this selectivity has been noted and described in a review of the mechanisms of ketamine action as an antidepressant [48]. In addition, another NMDAR antagonist, memantine, preferentially blocked the extrasynaptic NMDAR currents rather than synaptic currents [50]. In general, CaMKIIα is involved in physiological processes by interacting with various substrate molecules. It has been reported that CaMKIIα could stay at the postsynaptic site for a longer time by binding to GluN2B, and this interaction was considered to be crucial for synaptic structure and strength [51, 52]. The interaction between CaMKIIα and GluN2B in the extrasynaptic fraction of the hippocampus was not well understood, while the location of the protein was different, and its role in participating in physiological and pathological processes was also different [53, 54]. In the present study, ketamine administration attenuated the enhanced interaction between p-CaMKIIα and GluN2B in the extrasynaptic fraction of the hippocampus. CaMKIIα siRNA reduced the level and number of puncta of GluN2B in cultured hippocampal neurons. In addition, inhibition of CaMKIIα activity by KN93 reduced extrasynaptic GluN2B localization and phosphorylation in the hippocampus. Similarly, it has been shown that in a model of LPS-induced neuronal injury, GluN2B antagonists could reverse neuronal damage by disrupting a signaling complex such as GluN2B–CaMKII–PSD95 and further reducing the level of phosphorylated CaMKII [55]. In general, Ca2+ can flow into the cell through the GluN2B-containing NMDA receptors on the membrane, causing phosphorylation of CaMKIIα at the Thr286 site. Subsequently, activated CaMKIIα can phosphorylate the GluN2B receptor, further promoting Ca2+ influx into the cell. Therefore, CaMKIIα and the GluN2B receptor may interact in a positive feedback manner. Our data raise a possibility that CaMKIIα/GluN2B in the extrasynaptic fraction might play a key role in the antidepressant effects of ketamine by accelerating Ca2+ flow into the cell and causing neuronal dysfunction. Previous studies have showed that GluN2B-containing NMDA receptors are essential for ketamine’s antidepressant effects and GluN2B antagonist could rapidly reverse depressive-like behavior [11], our results may complement previous findings that extrasynaptic CaMKIIα is also involved in ketamine’s antidepressant effect, with downstream involvement of GluN2B.

Normal NMDARs activity is crucial to neurotransmission [56]. Excessively enhanced NMDARs activity can lead to intracellular calcium overload and trigger a series of pathological processes, including depression [57]. The specific effects of NMDARs activation depend on the subcellular localization of the receptor [58]. Synaptic NMDARs activation promotes CREB phosphorylation, whereas extrasynaptic NMDARs activation decreases CREB phosphorylation [59]. Furthermore, the BDNF gene is controlled by several transcription factors, and CREB plays a central role in this regulatory process [60]. Antidepressants can increase BDNF levels in the hippocampus, while viral knockout of BNDF in specific subregions of the hippocampus can induce depression-like behaviors [61]. In the present study, LPS injection decreased the levels of p-CREB and BDNF in the hippocampus, which were reversed by ketamine administration. These results suggested that CREB inhibition pathway induced by overactivated extrasynaptic GluN2B participated in ketamine’s antidepressant effects.

The disruption of synaptic plasticity is considered to be one of the neurobiological manifestations of depression [62]. AMPA receptors play a key role in the formation, maintenance, and homeostasis of synaptic plasticity [63]. It has been shown that AMPARs can be quickly transported to synapses during LTP [64]. Adult knockout mice lacking GluR1 do not show LTP, suggesting that the GluR1 subunit is essential for the production of LTP. It has been reported that fluoxetine can enhance the LTP in the hippocampus [65]. AMPAR subunits (GluR1 and GluR2) are upregulated in the hippocampus after ketamine administration [19]. Pre-treatment with the AMPAR antagonist NBQX can block the antidepressant effects of ketamine in animal models of depression [66, 67]. In the present study, ketamine prevented the impaired LTP induction induced by LPS. Moreover, it also significantly increased the level of GluR1 but did not alter the level of GluR2 in the hippocampal synaptosomes. These results suggested that ketamine’s antidepressant effects shifts from early functional plasticity to late structural homeostasis [48].

There are some limitations in our study. Firstly, we did not observe long-term changes in CaMKIIα after ketamine administration, which needs to be confirmed in further study. Secondly, clinical and animal studies have shown that the antidepressant effects of ketamine are gender dependent [68, 69]. Moreover, women are twice as likely as men to suffer from major depression [70]. Therefore, further study of ketamine is also required on gender differences. Thirdly, we did not verify whether overexpression of CaMKIIα could block ketamine’s antidepressant effects, which needs to be confirmed in our future study. Finally, it should be noted that the number of animals in our study is relatively small, we will include more mice in our further studies to make the evidence more reliable.

Conclusion

In conclusion, our results indicate that ketamine is effective in reversing LPS-induced depression-like behaviors, a process associated with decreased extrasynaptic CaMKIIα activity in the hippocampus. This further induces disturbance of extrasynaptic GluN2B localization and phosphorylation, which subsequently affected synaptic plasticity and induces depression-like behavior. Taken together, our study provides additional evidence that extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model, which will contribute to the development of the next generation of more effective and safer antidepressants.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Abbreviations

ACSF:

Artificial cerebrospinal fluid

BCA:

Bicinchoninic acid

CaMKII:

Calcium/calmodulin-dependent protein kinase II

CRP:

C-reactive protein

CRF1:

Corticotropin-releasing factor 1

DMSO:

Dimethyl sulfoxide

fEPSP:

Field excitatory postsynaptic potential

FST:

Forced-swimming test

HFS:

High-frequency stimulation

HDRS:

17-item Hamilton Depression Rating Scale

IL-6:

Interleukin 6

IL-10:

Interleukin 10

IL-1β:

Interleukin 1 beta

KN93:

C26H29ClN2O4S.H3O4P

LPS:

Lipopolysaccharide

NSAIDs:

Nonsteroidal anti-inflammatory drugs

NMDARs:

N-methyl-d-aspartate receptors

NSFT:

Novelty-suppressed feeding test

OFT:

Open-field test

PSD95:

Postsynaptic density-95

TNF-α:

Tumor necrosis factor-alpha

References

  1. 1.

    Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.

    PubMed  Article  Google Scholar 

  2. 2.

    Insel TR, Wang PS. The STAR*D trial: revealing the need for better treatments. Psychiatr Serv. 2009;60:1466–7.

    PubMed  Article  Google Scholar 

  3. 3.

    Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Hudmon A, Schulman H. Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem. 2002;71:473–510.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Wayman GA, Lee YS, Tokumitsu H, Silva AJ, Soderling TR. Calmodulin-kinases: modulators of neuronal development and plasticity. Neuron. 2008;59:914–31.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Kim TK, Kim JE, Park JY, Lee JE, Choi J, Kim H, et al. Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala. Neurobiol Dis. 2015;79:59–69.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Robison AJ, Vialou V, Sun HS, Labonte B, Golden SA, Dias C, et al. Fluoxetine epigenetically alters the CaMKIIalpha promoter in nucleus accumbens to regulate DeltaFosB binding and antidepressant effects. Neuropsychopharmacology. 2014;39:1178–86.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Adaikkan C, Taha E, Barrera I, David O, Rosenblum K. Calcium/calmodulin-dependent protein kinase II and eukaryotic elongation factor 2 kinase pathways mediate the antidepressant action of ketamine. Biol Psychiatry. 2018;84:65–75.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Vyklicky V, Korinek M, Smejkalova T, Balik A, Krausova B, Kaniakova M, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191–203.

    CAS  PubMed  Google Scholar 

  11. 11.

    Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife. 2014;3:e03581.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  12. 12.

    Kiselycznyk C, Jury NJ, Halladay LR, Nakazawa K, Mishina M, Sprengel R, et al. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behav Brain Res. 2015;287:89–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32:551–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001;411:801–5.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Barcomb K, Hell JW, Benke TA, Bayer KU. The CaMKII/GluN2B protein interaction maintains synaptic strength. J Biol Chem. 2016;291:16082–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci. 2012;35:607–18.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Colbran RJ. Targeting of calcium/calmodulin-dependent protein kinase II. Biochem J. 2004;378:1–16.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 2013;38:1609–16.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317–22.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Mendez-David I, Guilloux JP, Papp M, Tritschler L, Mocaer E, Gardier AM, et al. S 47445 produces antidepressant- and anxiolytic-like effects through neurogenesis dependent and independent mechanisms. Front Pharmacol. 2017;8:462.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  22. 22.

    Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Li SX, Han Y, Xu LZ, Yuan K, Zhang RX, Sun CY, et al. Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects. Mol Psychiatry. 2018;23:597–608.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Niu Y, Dai Z, Liu W, Zhang C, Yang Y, Guo Z, et al. Ablation of SNX6 leads to defects in synaptic function of CA1 pyramidal neurons and spatial memory. eLife. 2017;6.

  26. 26.

    Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14:511–22.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–9.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry. 2008;64:293–301.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Jiang Y, Wang Y, Sun X, Lian B, Sun H, Wang G, et al. Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model. Brain Behav. 2017;7:e00749.

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Benatti C, Blom JM, Rigillo G, Alboni S, Zizzi F, Torta R, et al. Disease-induced neuroinflammation and depression. CNS Neurol Disord Drug Targets. 2016;15:414–33.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Sandu RE, Buga AM, Uzoni A, Petcu EB, Popa-Wagner A. Neuroinflammation and comorbidities are frequently ignored factors in CNS pathology. Neural regeneration research. 2015;10:1349–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Dinan TG. Inflammatory markers in depression. Current opinion in psychiatry. 2009;22:32–6.

    PubMed  Article  Google Scholar 

  34. 34.

    Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry. 2013;18:332–9.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Lehrer S, Rheinstein PH. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce suicidal ideation and depression. Discov Med. 2019;28:205–12.

    PubMed  Google Scholar 

  36. 36.

    Kawasaki T, Ogata M, Kawasaki C, Ogata J, Inoue Y, Shigematsu A. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg. 1999;89:665–9.

    CAS  PubMed  Google Scholar 

  37. 37.

    Taniguchi T, Kanakura H, Takemoto Y, Kidani Y, Yamamoto K. Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats. Tohoku J Exp Med. 2003;200:85–92.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Thakurta RG, Das R, Bhattacharya AK, Saha D, Sen S, Singh OP, et al. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med. 2012;34:170–5.

    PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Yang C, Shen J, Hong T, Hu TT, Li ZJ, Zhang HT, et al. Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex. Mol Med Rep. 2013;8:887–90.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry. 2015;77:e19–20.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Schafer DP, Lehrman EK, Stevens B. The "quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS. Glia. 2013;61:24–36.

    PubMed  Article  Google Scholar 

  42. 42.

    Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151–7.

    PubMed  Article  Google Scholar 

  43. 43.

    Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26:469–79.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Vahid-Ansari F, Albert PR. Chronic fluoxetine induces sctivity changes in recovery from poststroke anxiety, depression, and cognitive impairment. Neurotherapeutics. 2018;15:200–15.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Huang L, Xi Y, Peng Y, Yang Y, Huang X, Fu Y, et al. A visual circuit related to habenula underlies the antidepressive effects of light therapy. Neuron. 2019;102:128–142.e128.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Zhu L, Yang L, Zhao X, Liu D, Guo X, Liu P, et al. Xanthoceraside modulates NR2B-containing NMDA receptors at synapses and rescues learning-memory deficits in APP/PS1 transgenic mice. Psychopharmacology (Berl). 2018;235:337–49.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Lo Iacono L, Gross C. Alpha-Ca2+/calmodulin-dependent protein kinase II contributes to the developmental programming of anxiety in serotonin receptor 1A knock-out mice. J Neurosci. 2008;28:6250–7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  48. 48.

    Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801–11.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Halt AR, Dallapiazza RF, Zhou Y, Stein IS, Qian H, Juntti S, et al. CaMKII binding to GluN2B is critical during memory consolidation. EMBO J. 2012;31:1203–16.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Martel MA, Ryan TJ, Bell KF, Fowler JH, McMahon A, Al-Mubarak B, et al. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron. 2012;74:543–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron. 2014;82:279–93.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol. 2006;572:789–98.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Song Y, Zhao X, Wang D, Zheng Y, Dai C, Guo M, et al. Inhibition of LPS-induced brain injury by NR2B antagonists through reducing assembly of NR2B-CaMKII-PSD95 signal module. Immunopharmacol Immunotoxicol. 2019:1–9.

  56. 56.

    Hardingham GE, Bading H. The yin and yang of NMDA receptor signalling. Trends Neurosci. 2003;26:81–9.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Kim YK, Na KS. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:117–26.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Kohr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 2006;326:439–46.

    PubMed  Article  CAS  Google Scholar 

  59. 59.

    Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405–14.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Vanhoutte P, Bading H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr Opin Neurobiol. 2003;13:366–71.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Taliaz D, Stall N, Dar DE, Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry. 2010;15:80–92.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Derkach VA, Oh MC, Guire ES, Soderling TR. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 2007;8:101–13.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Penn AC, Zhang CL, Georges F, Royer L, Breillat C, Hosy E, et al. Hippocampal LTP and contextual learning require surface diffusion of AMPA receptors. Nature. 2017;549:384–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Bath KG, Jing DQ, Dincheva I, Neeb CC, Pattwell SS, Chao MV, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology. 2012;37:1297–304.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349–52.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Fukumoto K, Iijima M, Chaki S. The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology. 2016;41:1046–56.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al. Gender differences in depression: findings from the STAR*D study. J Affect Disord. 2005;87:141–50.

    PubMed  Article  Google Scholar 

  69. 69.

    Picard N, Takesian AE, Fagiolini M, Hensch TK. NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity. Mol Psychiatry. 2019.

  70. 70.

    Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry. 2007;19:247–55.

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the MARC of Nanjing University and the staff for providing animal care during this study.

Funding

This study was supported by grants from the National Natural Science Foundation of China (to G.F.Z., No. 81503053, and Z.Q.Z., No. 81571083).

Author information

Affiliations

  1. Department of Anesthesiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China

    Xiao-Hui Tang, Guang-Fen Zhang, Ning Xu & Jian-Jun Yang

  2. Minister of Education Key Laboratory of Model Animal for Disease Study, Model Animal Research Center, Nanjing University, Nanjing, Jiangsu, China

    Gui-Fang Duan

  3. Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

    Min Jia, Ru Liu & Zhi-Qiang Zhou

  4. Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

    Jian-Jun Yang

Authors
  1. Xiao-Hui Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guang-Fen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ning Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gui-Fang Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Min Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ru Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhi-Qiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-Jun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XHT and GFZ designed this work. XHT wrote the paper. XHT, NX, and RL performed the experiments. XHT, MJ, and GFZ analyzed the data. ZQZ and JJY directed the discussion. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Zhi-Qiang Zhou or Jian-Jun Yang.

Ethics declarations

Ethics approval and consent to participate

All animal experiments and related operations are carried out in accordance with the Guideline for the Care and Use of Laboratory Animals from MARC of Nanjing University and the National Institutes of Health.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tang, X., Zhang, G., Xu, N. et al. Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model. J Neuroinflammation 17, 181 (2020). https://doi.org/10.1186/s12974-020-01843-z

Download citation

Keywords

  • Ketamine
  • Antidepressant
  • Extrasynaptic
  • CaMKIIα
  • GluN2B

Journal of Neuroinflammation

ISSN: 1742-2094